Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tirofiban - Medicure/Merck & Co

Drug Profile

Tirofiban - Medicure/Merck & Co

Alternative Names: Aggrastat; L 462; L 700462; MK 0383; MK 383; Tirofiban HCl; Tirofiban hydrochloride

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Merck & Co
  • Developer 4P Therapeutics; Aspen Pharmacare; Correvio Pharma; Eddingpharm; Medicure; University of Iowa
  • Class Anti-ischaemics; Anticoagulants; Antihaemorrhagics; Antithrombotics; Antivirals; Aromatic amino acids; Cardiovascular therapies; Ischaemic heart disorder therapies; Piperidines; Small molecules; Sulfonamides; Vascular disorder therapies
  • Mechanism of Action GPIIb-IIIa antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Acute coronary syndromes; Arterial thrombosis; Myocardial infarction; Unstable angina pectoris
  • Phase I/II Subarachnoid haemorrhage
  • No development reported Coronary artery restenosis; COVID 2019 infections

Most Recent Events

  • 02 Jan 2023 No development reported - Phase-II for COVID-2019 infections (Combination therapy) in Italy (IV)
  • 04 Nov 2021 Efficacy data from the phase II SAVI-PCI trial for Myocardial infarction and Unstable angina pectoris released by Medicure
  • 01 Jul 2021 University of Iowa completes a phase I/IIa trial in Subarachnoid haemorrhage (In adults, In the elderly) in USA (IV) (NCT03691727)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top